PPD Expands Medical Communications Operations into Asia-Pacific Region

WILMINGTON, N.C.

Pharmaceutical Product Development, LLC (PPD) has expanded its medical communications services into the Asia-Pacific region, enabling the contract research organization (CRO) to offer its portfolio of multi-lingual contact center services across the globe. By adding to its existing medical communications operations in North America, Latin America and Europe, PPD now is able to extend its services to biopharmaceutical clients in all regions of the world. PPD’s Asia-Pacific medical communications operations are managed by teams in Tokyo and Singapore.

“Expanding our multi-channel medical communications operations into Asia-Pacific strengthens our ability to provide our clients a single source of global medical information services. That ensures consistency of operations around the world while continuing to deliver high-quality health care services and expertise in an efficient, regulatory-compliant and customer-centric manner,” said Vivian Broach, vice president of operations and head of PPD’s medical communications operation. “There is strong demand for these services globally, and we have an experienced management team in place to oversee our operations and to create flexible and customized programs that meet our clients’ needs at either a global or regional level.”

PPD has 25 years of experience in medical information and safety contact center services. Through its experienced staff of pharmacists, physicians, nurses, medical writers and life science graduates, PPD provides a wide array of customized contact center services that includes medical information inquiry management, adverse event and product quality complaint management, patient support programs, support for risk evaluation and mitigation strategies (REMS), and medical content development. These services can be provided on a stand-alone basis or as part of a seamless, full-service solution that includes PPD’s other global post-approval offerings, such as pharmacovigilance, late-stage research, registries and observational studies, and real-world outcomes.

Since its formation in 1991, the PPD medical communications team has managed more than 16 million medical information inquiries, documented more than 3 million adverse events and product complaints, and supported more than 110 product launches. These efforts are complemented by a full-service, post-approval medical writing team, whose members have prepared more than 8,000 standard responses to address inquiries, as well as numerous dossiers, presentations and manuscripts.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

PPD Forward-Looking Statement

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s expansion of its medical communications services, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426006162/en/